A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs AST 008 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Exicure
- 16 Apr 2018 According to an Exicure media release, this study is expected to complete in mid 2018.
- 09 Mar 2018 According to a Exicure media release, the company anticipates results from this trial in 2018.
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.